Prescription attached:-
TC(1495)*.(12). ENT Department Case No (116)* — Nasal Obstruction: Probable Inflammatory/Allergic Rhinitis, with Structural Cause to Exclude; Six-Medicine Prescription Safety Review (1 Prescription + 0 Reports + 0 Clinical Images) | English + বাংলা
Author / লেখক: Md. Rafiqul Islam Lipu | LIPU MED | Reviewed: 03 November 2026 | Source prescription: 15 August 2026 | Specialty: ENT / নাক-কান-গলা | Patient identity: withheld in public article.
Website case-number check: On 03 November 2026, the public Medical Blog archive listed 1,492 posts and the ENT archive listed 115 posts. Its most recent visible ENT-labelled entry is TC(1488), ENT Case 115. Separate earlier LIPU MED unpublished drafts have used proposed TC(1493) and TC(1494). Therefore TC(1495)*, DCS/category marker (12), and ENT Case (116)* are proposed sequence labels, not yet reserved or published. The archive post count is not proof that the highest global TC equals that count; check all unpublished drafts and the live archive before posting. Numbering confidence 0.70; ENT next-category confidence 0.90 if no draft in progress.
Evidence legend: [D] visibly documented; [U] handwritten text uncertain; [V] brand/generic independently matched against MedEx; [I] reviewer inference, not a written physician diagnosis; [ND] not documented. Confidence 0.0–1.0 rates evidence/interpretation strength, not a validated disease probability.
Highest-priority safety finding / জরুরি ওষুধ যাচাই: Open 500 mg is phenoxymethylpenicillin (penicillin V), not a nasal decongestant. It is written 1–0–1 and the duration looks like “২ মাস” (two months); that duration is uncertain and requires immediate prescriber/pharmacist clarification, not automatic execution. The image provides no bacterial-infection criteria. Independently verify the indication for Indever/propranolol and whether Avaspray really means two sprays per nostril twice daily. Nothing in this article changes a prescription on the patient’s behalf.
01. Patient and Prescriber — Source Identity / রোগী ও চিকিৎসকের তথ্য
| Variable / বিষয় | Source-preserving interpretation / তথ্য | Status; confidence |
|---|---|---|
| Document date | 15 AUG 2026 [stamp]; 15-08-26 [handwritten] | [D] 0.99 |
| Age | Appears “২৮ বঃ” → about 28 years. Sex not independently documented. | [U] 0.88 |
| Name | Partly deliberately obscured in image; intentionally omitted from publication. | [D] 1.00 |
| Prescriber | Printed ENT Specialist; Dinajpur Medical College & Hospital, Dinajpur. Full name/registration not completely visible; professional credentials are not independently verified. | [D] 0.95 / [ND] registration |
| C/C | “Nasal obstruction” / নাক বন্ধ থাকা. | [D] 0.98 |
| Physician Dx | No legible diagnostic label in the dedicated field. | [ND] 0.96 |
| On/Exam | Unclear small mark/letters near the pulse row; no interpretable vital numeric value. BP/heart/lungs blank. | [U/ND] 0.95 |
| Source assets | 1 prescription; no laboratory report, CT, nasal endoscopy, allergy test, image of nasal cavity. | [D] 1.00 |
| Clinical context | Duration, laterality, seasonality, sneezing, itching, purulence, fever, sinus tenderness, prior surgery and current comorbidity are not stated. | [ND] 0.99 |
02. Definition, Etiology and Pathophysiology / সংজ্ঞা, কারণ, রোগপ্রক্রিয়া
Nasal obstruction / নাক বন্ধ: Reduced airflow through one or both nasal passages. It is a symptom, not a standalone etiologic diagnosis. Swollen mucosa, enlarged inferior turbinates, deviated septum, polyps, chronic rhinosinusitis and rarely a mass may produce the same complaint. Confidence 0.99 for the definition; cause undetermined in this patient.
Allergic rhinitis / অ্যালার্জিজনিত নাকের প্রদাহ: Allergen-specific IgE–mediated mast-cell activation releases histamine, leukotrienes and other mediators, resulting in congestion, sneezing, rhinorrhoea and pruritus; late inflammation contributes to persistent blockage. Avaspray plus probable Alcet supports a treatment intention, not proof that such symptoms were recorded. Patient working inference confidence 0.62.
Nonallergic rhinitis / অ্যালার্জি ছাড়া রাইনাইটিস: Temperature, fumes, smoke, irritants or autonomic responses can cause nasal obstruction without classical itching/sneezing. Working inference confidence 0.48.
Deviated nasal septum / নাকের পর্দা বেঁকে যাওয়া: Fixed anatomic obstruction can coexist with inflammatory mucosal swelling; intranasal steroids may reduce concurrent edema but cannot straighten a septum. A laterality examination and anterior rhinoscopy are needed. Working inference confidence 0.46.
Rhinosinusitis / নাক ও সাইনাসের প্রদাহ: Acute bacterial rhinosinusitis requires a compatible course and symptoms; chronic disease typically persists >12 weeks and requires objective confirmation. No such criteria are documented here. Confidence for proven bacterial sinusitis is low (<0.40), therefore it is not diagnosed.
03. Twenty-Item Prescription Documentation Audit / মূল প্রেসক্রিপশনের ২০টি তথ্যবিভাগ
1. C/C — Chief complaint / প্রধান অভিযোগ
Nasal obstruction / নাক বন্ধ [D]. Duration, side, pattern, triggers not supplied.
2. O/E — On examination / শারীরিক পরীক্ষা
No interpretable measured pulse or BP; small “HT?”-like mark unreadable [U]. Nasal mucosal appearance, septum, inferior turbinates, polyps and sinus tenderness not recorded.
3. I/H — Immunization history / টিকার ইতিহাস
Not documented [ND]; not routinely decisive for this presentation.
4. O/H — Occupational history / পেশাগত ইতিহাস
Not documented [ND]; occupation-related smoke, dust and chemical exposure should be elicited.
5. D/H — Drug history / পূর্ববর্তী ওষুধ
Previous antihistamines, nasal decongestants and β-blockers are not documented [ND]. Six items appear under the current Rx.
6. M/H — Medical history / পূর্বের রোগ
Asthma, wheeze, bradycardia, conduction disease, hypertension, migraine, rhinitis and drug allergies not documented [ND]. Relevant particularly to propranolol and penicillin.
7. O/S/E — Other systemic examination / অন্যান্য শারীরিক পরীক্ষা
No informative general/cardiorespiratory examination written [ND].
8. Plan — Treatment plan / চিকিৎসা পরিকল্পনা
Open, Ace, probable Alcet, Indever, Avaspray and Nasovap prescribed [D/U]. No explicit operation/endoscopy plan recorded.
9. O/G/E — Obstetric / gynecological / প্রসূতি-স্ত্রীরোগ ইতিহাস
Not documented and sex not ascertained [ND]; applicability cannot be presumed.
10. Advice / পরামর্শ
Nasovap printed steam instruction present; no reliably legible independent allergy-avoidance or follow-up advice [D/ND].
11. Doctor Dx / চিকিৎসকের লেখা রোগনির্ণয়
No explicit diagnosis legibly supplied [ND]. Do not convert medicine choice into physician-documented Dx.
12. Investigations / পরীক্ষা-নিরীক্ষা
No investigations ordered or results attached [ND].
13. Drugs / ওষুধ
Six items assessed individually below; brand spelling in Alcet/Avaspray is probable, not perfectly legible.
14. Reviewer working Dx / পর্যালোচকের রোগনির্ণয়
Symptomatic nasal obstruction with probable rhinitis; structural obstruction needs exclusion [I].
15. Medication–disease links / ওষুধ-রোগ সম্পর্ক
Avaspray/Alcet suggest anti-inflammatory and antihistamine intent; penicillin suggests suspected infection but does not establish it; Indever non-ENT indication unknown.
16. Explicit histories missing / অনুল্লিখিত গুরুত্বপূর্ণ ইতিহাস
Duration, unilateral vs bilateral, recurrent nosebleed, fever, purulence, watery discharge, sneezing, triggers, smell loss, prior decongestant use and penicillin allergy are missing.
17. Doctor vs reviewer / ডাক্তার ও পর্যালোচক
Doctor documented symptom and treatment, not formal Dx; LIPU MED supplies a provisional differential only.
18. Bangla diagnosis / বাংলা রোগনির্ণয়
নাক বন্ধ থাকার উপসর্গ—সম্ভাব্য অ্যালার্জি/প্রদাহজনিত রাইনাইটিস; নাকের গঠনগত বাধা বাদ দেওয়া প্রয়োজন।
19. Confidence / নির্ভরযোগ্যতা
Documented nasal obstruction 0.98; inflammatory rhinitis 0.68; specifically allergic subtype 0.62; proven acute bacterial sinusitis <0.40 (not adopted).
20. MedEx therapeutic classes / ওষুধের শ্রেণি
Narrow-spectrum penicillin, non-opioid analgesic, H1-antihistamine, nonselective β-blocker, intranasal corticosteroid, aromatic inhalation preparation.
04. Clinically Meaningful Observations / চিকিৎসকের নোট থেকে কী বোঝা যায়
The most defensible observation is nasal obstruction without documented examination findings (0.96). The combination of an intranasal corticosteroid and probable oral levocetirizine makes inflammatory/allergic rhinitis plausible (0.68), but the antibiotic, paracetamol and propranolol do not prove sinusitis, fever or anxiety. A two-month oral antibiotic instruction is either a major rationality concern or a transcription uncertainty; first confirm it (0.94).
A medication list cannot establish the patient’s current BP, pulse, heart rhythm, allergy history or bacterial phenotype. The source contains no objective evidence for a deviated septum, hypertrophy, polyps, or chronic sinusitis. Those remain questions for examination, not diagnoses.
05. Clinical Differential Diagnosis / সম্ভাব্য বিকল্প রোগ
| Condition / সম্ভাবনা | Supporting vs absent evidence / পক্ষে-বিপক্ষে | Reviewer confidence |
|---|---|---|
| Inflammatory rhinitis, possibly allergic | Nasal blockage + probable antihistamine and topical steroid. Sneezing, itching, pale boggy mucosa and clear rhinorrhoea not recorded. | 0.68 inflammation; 0.62 allergic subtype |
| Nonallergic rhinitis | Could cause congestion alone; irritant and trigger history absent. | 0.48 |
| Septal deviation (DNS) / টারবিনেট বৃদ্ধি | Common cause of sustained blockage, especially unilateral; anatomical examination unavailable. | 0.46 / 0.54 (unconfirmed) |
| Chronic rhinosinusitis ± nasal polyps | Would need ≥12-week symptoms and objective endoscopy/CT signs; not described. | 0.33; do not label confirmed |
| Acute bacterial rhinosinusitis | No ≥10-day persistent purulent syndrome, double-worsening or compatible findings supplied. | 0.25; rejected as established diagnosis |
| Rhinitis medicamentosa | Possible if topical decongestants used repeatedly; use history absent. | 0.30; unsubstantiated |
| Unilateral nasal mass / neoplasm | Must consider if progressive one-sided obstruction, bleeding or visible lesion; no such features currently documented. | Not assignable; rule out if alarm features |
06. Physician’s Dx vs Independent LIPU MED Dx / ডাক্তার ও পর্যালোচকের রোগনির্ণয়ের তুলনা
| Dimension | Physician document | LIPU MED independent working review |
|---|---|---|
| Explicit diagnosis / লিখিত Dx | None legible [ND]. | Undifferentiated nasal obstruction, probable inflammatory/allergic rhinitis; structural or other cause to be checked [I]. |
| Allergic rhinitis | Not written. | Plausible due to treatment pattern, but classic history/exam unrecorded. Confidence 0.62. |
| Bacterial infection | No bacterial diagnosis or diagnostic criteria. | Penicillin use alone does not establish infection; safety reassessment indicated. |
| Propranolol reason | Not stated. | Potential separate indication (e.g., palpitations/migraine) cannot be established from document. |
| Agreement / মিল | Symptom of nasal obstruction is explicit. | Reviewer agrees only with the documented symptom; adds evidence-limited differential. |
| Disagreement / অমিল | No explicit physician Dx for genuine disagreement. | Uncertain duration/dose and undocumented antibiotic/β-blocker indication are review flags, not accusations of error. |
07. Six Prescribed Medicines — Source Transcription / ছয়টি ওষুধের তালিকা
| # | Image reading | Verified / conditional generic | Dose and duration as read — NOT an approved repeat Rx | Evidence score |
|---|---|---|---|---|
| 1 | Tab. OPEN (500 mg) | Phenoxymethylpenicillin V | 1–0–1; duration looks “২ মাস” (two months) — critical verification | [D/U/V] 0.94 brand; 0.65 duration |
| 2 | Tab. ACE (500 mg) | Paracetamol | 1–0–1 for “১০ দিন” ≈10 days; confirm clinical need. | [D/V] 0.98; duration 0.90 |
| 3 | Tab. ALCET (probable reading; strength not written) | Levocetirizine 5 mg only if confirmed Alcet | 0–0–1; “২ মাস” ≈2 months. | [U/V] brand 0.78; generic conditional |
| 4 | Tab. INDEVER (10 mg) | Propranolol HCl | 1–0–1; “২ মাস” ≈2 months. | [D/V] 0.97; duration 0.84 |
| 5 | AVASPRAY (probable reading) | Fluticasone furoate 27.5 µg/spray if confirmed | Handwriting suggests “২ স্প্রে করে প্রতি নাকে দিনে ×২ বার” and “৩ মাস”/duration unclear; frequency must be reconciled. | [U/V] brand 0.74; frequency 0.67 |
| 6 | NASOVAP™ 2%+10% Suspension for Inhalation | Menthol 2% + eucalyptus oil 10% | Printed label with handwritten “2” (unit unclear), steam inhalation; “১৪ দিন” ≈14 days. | [D/V] 0.99 product; amount 0.40 |
Key decoding: 1–0–1 = morning and night; 0–0–1 = night. The sheet contains possible handwriting ambiguities. Do not dispense, continue or adjust a long antibiotic course based on this transcription alone. All six medications are analyzed below with 17 MedEx fields.
08. Six Individual Medicines — Full 17-Field MedEx Reviews / প্রতিটি ওষুধের ১৭ তথ্য
1. Open 500 mg — phenoxymethylpenicillin V
| MedEx parameter / ১৭টি যাচাই বিষয় | Source-based clinical interpretation / প্রমাণভিত্তিক পর্যালোচনা |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Phenoxymethylpenicillin (penicillin V) 500 mg; narrow-spectrum β-lactam antibiotic. |
| 2. Brand / ব্র্যান্ড | Open; Opsonin Pharma Ltd. |
| 3. Alternatives in Bangladesh / বিকল্প | Penvik DS 500 mg (Square; same generic/strength). Other penicillin V brands exist at 250 mg; do not compare across strengths as equivalent tablets. |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Narrow-spectrum penicillin / সংকীর্ণ কার্যপরিসরের অ্যান্টিবায়োটিক. |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | β-lactam; penicillin-binding-protein inhibitor. |
| 6. Main purpose / প্রধান কাজ | Treat confirmed or clinically justified susceptible bacterial infection, not isolated nasal blockage. |
| 7. Patient-specific reason / কেন দেওয়া হয়ে থাকতে পারে | Only nasal obstruction is documented; rationale for antibiotic cannot be established. Important stewardship question (0.93 confidence of documentation gap). |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Rash, nausea/diarrhoea; rare anaphylaxis, C. difficile-associated colitis; prolonged use can select resistant flora. |
| 9. Verified MedEx link / সরাসরি মেডএক্স | Open independently verified MedEx monograph |
| 10. Unit/strip price and formulation / দাম | ৳5.50/tablet; ৳55 per 10-tablet strip (MedEx listing at review). |
| 11. Mechanism of action / কার্যপদ্ধতি | Binds PBPs and blocks bacterial cell-wall cross-linking; bactericidal against susceptible organisms. |
| 12. Approved uses / ইন্ডিকেশন | Penicillin-susceptible tonsillopharyngitis and selected ENT/skin infections when clinically appropriate; not a default for undifferentiated nasal obstruction. |
| 13. Interactions + contraindications / মিথস্ক্রিয়া ও নিষেধ | Contraindicated with prior serious penicillin hypersensitivity; caution with methotrexate (toxicity), probenecid and warfarin (INR monitoring). |
| 14. Precautions and monitoring / সতর্কতা | Clarify penicillin-allergy history; assess fever, purulence and duration; consider infection diagnosis before any course. Severe/persistent diarrhoea warrants urgent assessment. |
| 15. Dosage, frequency, duration / ডোজ | Image 1–0–1; length resembles “২ মাস” but uncertain. DO NOT interpret this as an acceptable two-month antibiotic plan. MedEx adult guidance is usually 250–500 mg every 6 hours depending on infection. Correct indication, dose, and duration are prescriber decisions. |
| 16. Pregnancy + lactation / গর্ভাবস্থা-স্তন্যদান | May be considered in pregnancy or breastfeeding when specifically indicated; infant diarrhoea/thrush monitoring may be relevant. |
| 17. Other forms / combinations / অন্যান্য ফর্ম | Open 250 mg tablet and 125 mg/5 mL suspension; strength-specific prescribing required. |
Safety verdict: verify any “2-month” duration and why an antibiotic is needed before proceeding; an isolated nasal obstruction is not an antibiotic indication. Review confidence 0.90 for safety concern.
2. Ace 500 mg — paracetamol
| MedEx parameter / ১৭টি যাচাই বিষয় | Source-based clinical interpretation / প্রমাণভিত্তিক পর্যালোচনা |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Paracetamol (acetaminophen) 500 mg. |
| 2. Brand / ব্র্যান্ড | Ace; Square Pharmaceuticals PLC. |
| 3. Alternatives in Bangladesh / বিকল্প | Napa 500 mg; other paracetamol 500-mg tablets when product verified; avoid doubling with cold/flu combinations. |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Non-opioid analgesic and antipyretic / ব্যথা ও জ্বর কমায়. |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Centrally acting analgesic with antipyretic effect. |
| 6. Main purpose / প্রধান কাজ | Relieve fever or mild-to-moderate pain. |
| 7. Patient-specific reason / কেন দেওয়া হয়ে থাকতে পারে | No pain or fever is written; possible symptomatic intent only (0.45). |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Usually tolerated at recommended dose; overdose causes potentially fatal hepatotoxicity; rare severe skin reaction. |
| 9. Verified MedEx link / সরাসরি মেডএক্স | Open independently verified MedEx monograph |
| 10. Unit/strip price and formulation / দাম | ৳1.20 per tablet; ৳12 per 10-tablet strip (MedEx). |
| 11. Mechanism of action / কার্যপদ্ধতি | Central modulation of prostaglandin pathways and hypothalamic temperature control. |
| 12. Approved uses / ইন্ডিকেশন | Headache, fever, earache, facial discomfort and other pain/fever conditions. |
| 13. Interactions + contraindications / মিথস্ক্রিয়া ও নিষেধ | Overlapping acetaminophen-containing products, chronic heavy alcohol use, warfarin with repeated regular use; severe liver disease demands caution. |
| 14. Precautions and monitoring / সতর্কতা | Check weight/liver history, other OTC products, alcohol consumption and whether pain/fever actually exists. |
| 15. Dosage, frequency, duration / ডোজ | Image 1–0–1 for ≈10 days [U]. Adult usual 500–1,000 mg per dose every 4–6 h if required; prefer conservative daily maximum ≤3 g without clinician direction, never exceed 4 g/day in otherwise healthy adults. No automatic 10-day fixed schedule when asymptomatic. |
| 16. Pregnancy + lactation / গর্ভাবস্থা-স্তন্যদান | Often preferred short-term for pain/fever when clinically indicated during pregnancy; discuss prolonged use. Generally compatible with lactation. |
| 17. Other forms / combinations / অন্যান্য ফর্ম | 500 mg, 665 mg XR and 1,000 mg brand strengths; different products require different dose intervals. |
Safety verdict: use for an actual pain/fever indication; review overall daily paracetamol intake. Review confidence 0.90 for safety concern.
3. Alcet (probable) 5 mg — levocetirizine
| MedEx parameter / ১৭টি যাচাই বিষয় | Source-based clinical interpretation / প্রমাণভিত্তিক পর্যালোচনা |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Levocetirizine dihydrochloride 5 mg if the word is indeed “Alcet”; no strength is clearly written on the photo. |
| 2. Brand / ব্র্যান্ড | Alcet, Healthcare Pharmaceuticals Ltd. Probable handwriting match only (0.78). |
| 3. Alternatives in Bangladesh / বিকল্প | Acitrin-L 5 mg; Curin 5 mg; same generic and dosage form after exact identification. |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Second-generation antihistamine / দ্বিতীয় প্রজন্মের অ্যান্টিহিস্টামিন. |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Selective H1-receptor inverse agonist. |
| 6. Main purpose / প্রধান কাজ | Reduce sneezing, itching, watery discharge and allergy-related rhinitis symptoms. |
| 7. Patient-specific reason / কেন দেওয়া হয়ে থাকতে পারে | Antiallergic intent plausible; classic features absent from recorded C/C (0.62). |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Somnolence in some patients, fatigue, dry mouth, headache; occasional urinary difficulty. |
| 9. Verified MedEx link / সরাসরি মেডএক্স | Open independently verified MedEx monograph |
| 10. Unit/strip price and formulation / দাম | ৳4.50 per 5-mg tablet; ৳45 per 10-tablet strip (MedEx). |
| 11. Mechanism of action / কার্যপদ্ধতি | Blocks histamine H1 signaling and reduces immediate allergic symptoms. |
| 12. Approved uses / ইন্ডিকেশন | Seasonal/perennial allergic rhinitis; chronic urticaria. |
| 13. Interactions + contraindications / মিথস্ক্রিয়া ও নিষেধ | Other sedatives/alcohol may increase drowsiness; contraindicated in known hypersensitivity and severe renal failure (CrCl <10 mL/min). |
| 14. Precautions and monitoring / সতর্কতা | Check renal function for impaired patients and alertness for driving; may contribute less to pure congestion than intranasal steroid. |
| 15. Dosage, frequency, duration / ডোজ | Image 0–0–1 for apparently 2 months. If confirmed Alcet 5 mg, standard adult 5 mg once daily; renal adjustments require clinician assessment. |
| 16. Pregnancy + lactation / গর্ভাবস্থা-স্তন্যদান | Use pregnancy only when appropriate under clinician assessment; consult on breastfeeding because small quantities appear in milk and infant effects warrant review. |
| 17. Other forms / combinations / অন্যান্য ফর্ম | 5-mg tablet and 2.5 mg/5 mL solution. No strength appears unambiguously in source photo. |
Safety verdict: name and tablet strength need confirmation before this 5-mg generic assumption is used. Review confidence 0.90 for safety concern.
4. Indever 10 mg — propranolol hydrochloride
| MedEx parameter / ১৭টি যাচাই বিষয় | Source-based clinical interpretation / প্রমাণভিত্তিক পর্যালোচনা |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Propranolol hydrochloride 10 mg. |
| 2. Brand / ব্র্যান্ড | Indever; ACI Limited. |
| 3. Alternatives in Bangladesh / বিকল্প | Use equivalent propranolol products only after exact product/strength confirmation; no alternate 10-mg brand priced in this review. |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | β-adrenoceptor blocker / বিটা-ব্লকার. |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Nonselective β1/β2-adrenergic antagonist. |
| 6. Main purpose / প্রধান কাজ | Certain tachyarrhythmias, hypertension, migraine prophylaxis, essential tremor, and somatic symptoms of anxiety where indicated. |
| 7. Patient-specific reason / কেন দেওয়া হয়ে থাকতে পারে | No HR/BP, palpitations, thyroid condition or migraine history documented; ENT indication not demonstrated (0.95). Could be for a separate undocumented condition. |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Bradycardia, hypotension, fatigue, dizziness, sleep disturbance; potential bronchospasm and masking hypoglycemia symptoms. |
| 9. Verified MedEx link / সরাসরি মেডএক্স | Open independently verified MedEx monograph |
| 10. Unit/strip price and formulation / দাম | ৳0.51 per 10-mg tablet; ৳10.20 per 20-tablet strip (MedEx). |
| 11. Mechanism of action / কার্যপদ্ধতি | Blocks catecholamine activation of cardiac β1 and bronchial β2 receptors, reducing pulse and cardiac adrenergic response. |
| 12. Approved uses / ইন্ডিকেশন | Selected cardiovascular disease, migraine prophylaxis, tremor, some anxiety symptoms; not standard treatment for nasal obstruction. |
| 13. Interactions + contraindications / মিথস্ক্রিয়া ও নিষেধ | Avoid in asthma/bronchospasm, marked bradycardia, higher-degree heart block, cardiogenic shock. Caution verapamil/diltiazem, insulin, other rate-lowering drugs and bronchodilator β2 agonists. |
| 14. Precautions and monitoring / সতর্কতা | Before use/review: HR, BP, respiratory wheeze/asthma history, diabetes and actual prescriber diagnosis. Do not abruptly stop chronic propranolol without clinician advice. |
| 15. Dosage, frequency, duration / ডোজ | Image 1–0–1 for about 2 months; role and dose must be checked. Dose is indication dependent; no ENT-based dose endorsed here. |
| 16. Pregnancy + lactation / গর্ভাবস্থা-স্তন্যদান | Maternal–fetal/newborn β-blockade effects possible; specialist risk–benefit assessment and neonatal observation may be necessary. Breastfeeding decisions individualized. |
| 17. Other forms / combinations / অন্যান্য ফর্ম | Indever also listed as 20-mg and 40-mg tablets; not direct substitutions. |
Safety verdict: no documented cardiovascular indication, and asthma/bradycardia checks are missing. Clarify with the prescriber; do not abruptly stop if the patient already takes it regularly. Review confidence 0.90 for safety concern.
5. Avaspray (probable) — fluticasone furoate nasal spray
| MedEx parameter / ১৭টি যাচাই বিষয় | Source-based clinical interpretation / প্রমাণভিত্তিক পর্যালোচনা |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Fluticasone furoate 27.5 microgram per metered nasal spray if the brand is Avaspray. |
| 2. Brand / ব্র্যান্ড | Avaspray; Square Pharmaceuticals PLC. Handwriting “…spray” resembles Avaspray (0.74 confidence). |
| 3. Alternatives in Bangladesh / বিকল্প | Flutica, F-Son, Neotison, Rhinomist, Snofas 27.5 µg/spray (same generic/strength; compare pump and directions). |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Intranasal steroid / নাকে প্রয়োগযোগ্য কর্টিকোস্টেরয়েড. |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Glucocorticoid receptor agonist with local anti-inflammatory effect. |
| 6. Main purpose / প্রধান কাজ | Improve nasal mucosal inflammation, congestion and other rhinitis symptoms. |
| 7. Patient-specific reason / কেন দেওয়া হয়ে থাকতে পারে | Most directly connected drug to recorded nasal obstruction if inflammatory cause. Confirm name, schedule and diagnosis (0.77). |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Epistaxis, nasal soreness/dryness, headache; rare septal irritation/perforation, hypersensitivity, ocular pressure or cataract concerns with prolonged exposure. |
| 9. Verified MedEx link / সরাসরি মেডএক্স | Open independently verified MedEx monograph |
| 10. Unit/strip price and formulation / দাম | ৳275 per 120 metered sprays (MedEx listing). |
| 11. Mechanism of action / কার্যপদ্ধতি | Suppresses inflammatory-cell signaling, eosinophilic activation and mediator production in nasal mucosa. |
| 12. Approved uses / ইন্ডিকেশন | Seasonal and perennial allergic rhinitis. |
| 13. Interactions + contraindications / মিথস্ক্রিয়া ও নিষেধ | Strong CYP3A4 inhibitors including ritonavir/cobicistat can raise systemic steroid exposure; caution with other steroids and active untreated nasal infections. |
| 14. Precautions and monitoring / সতর্কতা | Aim spray away from septum toward outer nasal wall; shake and prime as label directs. Check recurrence of nosebleeds or recent nasal surgery. |
| 15. Dosage, frequency, duration / ডোজ | Text resembles “two sprays each nostril twice daily” but handwriting uncertain. Brand usual adult starting schedule is two sprays in each nostril once daily; MedEx notes selected higher regimens can be used by clinician. Do not assume BID is intended. Duration may read “৩ মাস”; verify. |
| 16. Pregnancy + lactation / গর্ভাবস্থা-স্তন্যদান | Consider if benefit outweighs risk; low systemic exposure with correctly used nasal spray, but individualized pregnancy/lactation assessment required. |
| 17. Other forms / combinations / অন্যান্য ফর্ম | 120-metered-dose nasal suspension, 27.5 µg/actuation. Other fluticasone propionate 50 µg/spray is not an identical formulation. |
Safety verdict: verify twice-daily vs once-daily spray schedule. Correct technique is essential. Review confidence 0.90 for safety concern.
6. Nasovap 2%+10% — menthol and eucalyptus oil inhalation suspension
| MedEx parameter / ১৭টি যাচাই বিষয় | Source-based clinical interpretation / প্রমাণভিত্তিক পর্যালোচনা |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Menthol 2% + eucalyptus oil 10% suspension for inhalation. |
| 2. Brand / ব্র্যান্ড | Nasovap; Square Pharmaceuticals PLC. |
| 3. Alternatives in Bangladesh / বিকল্প | No verified composition-identical alternative brand documented in this review; saline nasal irrigation is a different, guideline-based modality, not a chemical substitute. |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Symptom-relieving aromatic inhalation preparation / ভাপের সঙ্গে ব্যবহৃত উপসর্গ-উপশমকারী প্রস্তুতি. |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Menthol TRPM8 sensory-cooling effect + eucalyptus volatile aromatic preparation; not a proven bacterial cure. |
| 6. Main purpose / প্রধান কাজ | Subjective relief of stuffy-nose sensation during colds and nasal congestion. |
| 7. Patient-specific reason / কেন দেওয়া হয়ে থাকতে পারে | Symptom-relief intent consistent with nasal blockage; does not establish mechanism or infection (0.83). |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Skin/airway irritation, allergy, possible wheezing/bronchospasm especially asthma; scald burns if unsafe water temperature; dangerous if swallowed. |
| 9. Verified MedEx link / সরাসরি মেডএক্স | Open independently verified MedEx monograph |
| 10. Unit/strip price and formulation / দাম | ৳130 for a 100-mL bottle (MedEx). |
| 11. Mechanism of action / কার্যপদ্ধতি | Menthol can alter nasal airflow perception via cold-sensitive receptors; eucalyptus vapors may feel decongesting, but do not reliably correct structural obstruction. |
| 12. Approved uses / ইন্ডিকেশন | Symptomatic relief with coughs, colds and blocked noses. |
| 13. Interactions + contraindications / মিথস্ক্রিয়া ও নিষেধ | Avoid if menthol/eucalyptus hypersensitivity; inhaled vapors can trigger bronchospasm in susceptible patients. |
| 14. Precautions and monitoring / সতর্কতা | For external inhalation only, never swallow or instill directly into nostril. Avoid hot steam burns; no boiling water. Avoid in young infants and use caution in asthma. |
| 15. Dosage, frequency, duration / ডোজ | Prescription sticker has handwritten “2” with unclear unit, apparently for 14 days. MedEx manufacturer directions: 5 mL in 500–600 mL hot (not boiling) water, inhale vapor as directed, repeat after 4 hours if required. Do not translate “2” into mL or capfuls without checking. |
| 16. Pregnancy + lactation / গর্ভাবস্থা-স্তন্যদান | MedEx notes inhalation as directed is unlikely to have ill effects, but avoid excessive exposure and discuss respiratory sensitivity. |
| 17. Other forms / combinations / অন্যান্য ফর্ম | 100-mL 2%+10% suspension. Not a nebulizer drug, injectable product or nasal spray. |
Safety verdict: volume unit unclear, inhalation only; scalding injury and bronchospasm risks apply. Review confidence 0.90 for safety concern.
09. Bangladesh Alternatives and Price Comparison / বিকল্প ব্র্যান্ড ও আনুমানিক মূল্য
| Drug | Matched comparison / একই জেনেরিকের বিকল্প | Listed price (BDT) and limits |
|---|---|---|
| Open 500 | Penvik DS 500; same penicillin V strength | Open ৳5.50/tablet; Penvik DS price should be reconfirmed on current listing; antibiotic not substitutable without clinical need. |
| Ace 500 | Other 500-mg paracetamol brands, e.g., Napa after package verification | Ace ৳1.20/tablet; 10-tablet strip ৳12. |
| Probable Alcet 5 | Acitrin-L 5, Curin 5; verify image first | Alcet ৳4.50/tablet; 10-tablet strip ৳45. |
| Indever 10 | Same-generic propranolol options require pharmacy confirmation | Indever ৳0.51/tablet; 20-tablet strip ৳10.20. |
| Probable Avaspray 27.5 | Flutica, F-Son, Neotison, Rhinomist 27.5 µg/spray | Avaspray ৳275/120 actuations; F-Son ৳250/120 actuations (MedEx listing). |
| Nasovap 2%+10% | No composition-identical alternative confirmed | Nasovap ৳130 per 100 mL. |
These are listed reference prices, not live pharmacy quotes. Formulation, concentration, prescription indication and dosing matter more than a brand-price match. All pricing should be reconfirmed before publication or purchase.
10. Prioritized Prescription Safety Audit / ঝুঁকির অগ্রাধিকার
| Priority | Audit flag / নিরাপত্তা প্রশ্ন | Clinically defensible action |
|---|---|---|
| Critical | Open 500 mg antibiotic appears 1–0–1 for “২ মাস”; no documented bacterial syndrome. | Reconcile drug, duration, allergy history and infection indication with prescriber before treatment or refill. Never infer long-term antibiotic prophylaxis. |
| High | Indever 10 mg twice daily, no HR/BP or β-blocker indication, no asthma status. | Check previous history, measured HR/BP, wheeze/asthma, bradycardia, conduction problems and concomitant medicine list. |
| Moderate–High | Avaspray BID handwritten vs standard adult initial once-daily schedule. | Confirm spray frequency, total daily actuations and planned duration; check epistaxis and technique. |
| Moderate | Alcet handwriting/strength and prolonged two-month use. | Confirm brand, strength, renal function where relevant, sedation and symptom response. |
| Moderate | Ace schedule without documented fever or pain. | Confirm symptom indication, avoid unnecessary fixed course/duplicate OTC paracetamol. |
| Moderate | Nasovap unit unclear and steam exposure. | Do not swallow; clarify mL amount, use hot not boiling water, consider safer saline irrigation instead if scald risk. |
11. Fourteen Advanced Clinical Assessment Parameters / ১৪টি উন্নত ক্লিনিক্যাল বিশ্লেষণ
1. Clinical Decision-Making Algorithm / চিকিৎসা-সিদ্ধান্তের ধাপ
First establish laterality and duration → eliciting allergy/viral/bacterial symptoms, red flags and medication history → anterior rhinoscopy (± ENT nasal endoscopy) → categorize inflammatory vs structural → treat according to verified diagnosis → reassess adherence and symptoms. No CT just for one unexplored symptom. Confidence 0.95.
2. Diagnostic Evidence and Uncertainty / অনিশ্চয়তার মূল্যায়ন
Nasal obstruction 0.98; probable inflammatory rhinitis 0.68; specific allergic rhinitis 0.62; DNS not confirmed (0.46); acute bacterial sinusitis not supported (0.25). Diagnostic confidence scores are heuristic evidence-rating, not probabilities. Confidence 0.94.
3. Prescription Safety and Deprescribing Audit / ওষুধ নিরাপত্তা
Check appropriateness of penicillin V and propranolol, plus frequency of nasal steroid; avoid duplicative antihistamine or acetaminophen. Do not unilaterally discontinue existing β-blocker or start/extend antibiotics. Confidence 0.97.
4. Red Flags and Emergency Referral / বিপদচিহ্ন
Same-day/urgent ENT or emergency review for severe unilateral progressive obstruction with bleeding, unilateral foul discharge, visible mass, orbital swelling, vision change, proptosis, severe headache with neurological symptoms, fever with systemic toxicity, or difficult breathing; immediate emergency care for anaphylaxis after antibiotic. Confidence 0.95.
5. Evidence-Based Treatment Comparison / চিকিৎসা তুলনা
If inflammatory/allergic rhinitis is established: intranasal corticosteroid is evidence-supported; add oral second-generation antihistamine primarily for sneezing/itch; saline helps symptoms. Fixed intranasal antihistamine+steroid may help moderate/severe cases. Antibiotics are not routine for uncomplicated rhinitis. Confidence 0.98.
6. Follow-up and Outcomes / ফলোআপ ও ফলাফল
For uncomplicated symptoms, reassess technique, symptom score and exam after 2–4 weeks of consistent topical treatment; earlier if red flags or worsening. Record NOSE/VAS score or congestion days, sleep quality, adverse effects and laterality; refer persistent structural symptoms. Confidence 0.90.
7. Investigation Interpretation / পরীক্ষার প্রয়োজন
No reports attached: none can be interpreted. Anterior rhinoscopy is first-line; nasal endoscopy with persistent unilateral or unclear symptoms; IgE/skin testing when allergy diagnosis will change management; noncontrast CT for objectively suspected chronic sinus disease or selected surgery, not initial unselected congestion. Confidence 0.96.
8. Patient Education in Bangla / রোগী শিক্ষা
নাক বন্ধ থাকলেই সাইনাসে ব্যাকটেরিয়া হয়েছে ধরে অ্যান্টিবায়োটিক খাবেন না। নাকের স্প্রে নাকের মাঝের পর্দার দিকে নয়, বাইরের দেয়ালের দিকে তাক করে ব্যবহার করতে হয়। গরম পানির ভাপে পুড়ে যাওয়ার ঝুঁকি আছে। শ্বাসকষ্ট/নাক দিয়ে বারবার রক্ত/চোখ ফুলে গেলে দ্রুত চিকিৎসা নিন। Confidence 0.97.
9. Guideline Update + Evidence Quality / গাইডলাইন মান
2024–25 ARIA–EAACI intranasal treatment recommendations are strong/moderate evidence for steroid vs no treatment; the 2025 AAO-HNS sinusitis update discourages empiric antibiotic use without a clinical bacterial syndrome. These data are guideline-level but not case-confirmatory. Confidence 0.98.
10. Medical SEO and Transparency / ব্লগ প্রকাশনায় স্বচ্ছতা
Suggested SEO title: “Nasal Obstruction Prescription Review: Open, Indever, Avaspray & Safety | LIPU MED”. Meta description: “Bangla-English ENT prescription review of nasal obstruction, probable rhinitis, and antibiotic, beta-blocker and steroid-spray safety.” State case numbering is proposed and diagnosis is provisional. Confidence 0.96.
11. Guideline-Based Additional Drug Assessment / অতিরিক্ত ওষুধ বিবেচনা
If obstruction from allergic rhinitis persists, clinician may consider an intranasal antihistamine or fixed combination with steroid after assessing adherence, side effects, cost. Saline irrigation may be added as supportive care. Do not suggest another oral antibiotic absent ABRS criteria. Confidence 0.95.
12. Additional Investigations for Confirmation / আরও পরীক্ষা
Focused nasal history + anterior rhinoscopy first. Nasal endoscopy for one-sided/persistent symptoms, possible polyp, bleeding, suspicious lesion or failed adequate therapy. Allergy testing if needed for targeted avoidance or immunotherapy. Imaging only for appropriate sinus/anatomic indications. Confidence 0.96.
13. Polypharmacy and Unnecessary Drugs / অপ্রয়োজনীয় ওষুধ
Six items for one documented symptom is a signal for reconciliation, not automatically proof of inappropriate prescribing: the prescriber may have seen additional issues not recorded. Open and Indever have the most serious indication gaps; Ace may be conditional. Confidence 0.97.
14. Patient Counselling and Administration / সেবনবিধি
Avoid direct swallowing of Nasovap; shake and prime Avaspray, aim laterally, gentle sniff, wipe nozzle; take levocetirizine at night if drowsy; watch penicillin allergy; maintain medication list; never stop established propranolol suddenly. Correct the unreadable instructions with the issuing doctor/pharmacist before use. Confidence 0.98.
12. Demonstration Clinical Prescription Note — NOT FOR DISPENSING / উদাহরণ প্রেসক্রিপশন নোট
Demo only; not a substitute Rx: C/C: Nasal obstruction (duration/laterality unspecified). O/E: Nasal exam and vitals pending. Dx: Symptomatic nasal obstruction — probable inflammatory rhinitis; allergic subtype to confirm; rule out deviated nasal septum/turbinate hypertrophy. Plan: elicit history, perform rhinoscopy, review allergy and drug history, verify Open/Indever indications and Avaspray schedule, select appropriate topical treatment per examination; reassess 2–4 weeks. No antibiotic, β-blocker or empiric substitute prescribed by this review.
13. Referral Pathway / কোন বিশেষজ্ঞের কাছে যাবেন?
ENT/Otorhinolaryngology / নাক-কান-গলা বিশেষজ্ঞ: Primary referral for persistent blockage, recurrent one-sided symptoms, visible polyp, suspected septal deviation or unexplained failure of optimized medical therapy. Allergy/Immunology: recurring exposure-triggered rhinitis or consideration of allergen immunotherapy. Internal Medicine/Cardiology: clarify propranolol indication, HR/BP and cardiorespiratory contraindications; prescriber contact is preferable to unilateral changes. Urgent ENT or emergency care for the danger signs in Section 11.
14. Overview / Summary — সারসংক্ষেপ
Summary: An approximately 28-year-old patient received an ENT prescription dated 15 August 2026 for nasal obstruction. No formal physician diagnosis or nasal examination findings are legible. Probable inflammatory/allergic rhinitis is a reasonable provisional working hypothesis, while septal deviation/turbinate disease must be examined. The six prescribed items include Open (penicillin V), Ace (paracetamol), probable Alcet (levocetirizine), Indever (propranolol), probable Avaspray (fluticasone furoate) and Nasovap (menthol/eucalyptus). Clarification of a possible two-month penicillin V instruction, propranolol indication and nasal-spray frequency comes before judging treatment appropriateness. Overall case diagnostic evidence strength: 0.65.
বাংলা সারসংক্ষেপ: ১৫ আগস্ট ২০২৬ তারিখের প্রেসক্রিপশনে প্রধান অভিযোগ “নাক বন্ধ”। রোগের নির্দিষ্ট নাম বা নাকের পরীক্ষার ফল লেখা নেই। অ্যালার্জি/প্রদাহজনিত রাইনাইটিস থাকতে পারে, আবার নাকের পর্দা বাঁকা বা টারবিনেট বড় হওয়ার কারণেও নাক বন্ধ হতে পারে। Open 500 mg অ্যান্টিবায়োটিক; এটি দীর্ঘদিন সেবনের নির্দেশ আছে কি না এবং কেন দেওয়া হয়েছে তা দ্রুত চিকিৎসক/ফার্মাসিস্টের সঙ্গে মিলিয়ে নিতে হবে। Indever 10 mg বিটা-ব্লকার—নাক বন্ধের নিয়মিত ওষুধ নয়; অন্য কারণে দেওয়া হতে পারে। Avaspray-এর ব্যবহারের বারসংখ্যাও নিশ্চিত করা জরুরি।
15. Actionable Plan / করণীয়
- Immediately reconcile the written Rx: ask issuing ENT clinician/pharmacist to confirm Open 500 mg duration/indication, Alcet brand/strength, Indever indication and Avaspray dose. Do not extrapolate from photo.
- Take focused history: blockage duration, unilateral/bilateral, allergic symptoms, discharge type, fever, facial pain, nasal bleeding, smell loss, prior drops, drug allergy, asthma, palpitations/migraine.
- Perform ENT examination: vital signs plus anterior rhinoscopy, and nasal endoscopy when persistent/one-sided or otherwise indicated.
- Use evidence-matched treatment: if rhinitis confirmed, clinician-led intranasal anti-inflammatory therapy with correct technique and perhaps saline; avoid unjustified empiric antibiotic.
- Follow up: review nasal airflow/sleep, adherence and adverse effects in 2–4 weeks; urgent earlier assessment if red flags appear.
16. Final Clinical Judgment / চূড়ান্ত ক্লিনিক্যাল সিদ্ধান্ত
Final prescription-style working diagnosis / চূড়ান্ত সম্ভাব্য রোগনির্ণয়: Dx: NASAL OBSTRUCTION — PROBABLE INFLAMMATORY RHINITIS (ALLERGIC SUBTYPE POSSIBLE); RULE OUT DEVIATED NASAL SEPTUM / INFERIOR TURBINATE HYPERTROPHY. বাংলা: নাক বন্ধ—সম্ভাব্য প্রদাহজনিত রাইনাইটিস (অ্যালার্জিজনিত হতে পারে); নাকের পর্দা বেঁকে যাওয়া/নাসারন্ধ্রের টারবিনেট বড় হওয়া বাদ দিতে হবে।
Doctor’s written Dx: None legible. Working Dx confidence: 0.68 inflammatory rhinitis, 0.62 allergic subtype. Drug-brand confidence: Open 0.99; Ace 0.99; Alcet 0.78; Indever 0.99; Avaspray 0.74; Nasovap 1.00. Patient safety review confidence: 0.95. These scores do not substitute for patient assessment.
Publication disclaimer: Clinical educational review based on one image, not direct consultation. Brand-dose ambiguities and potential Rx safety issues require clinician/pharmacist reconciliation. Patient identifying information intentionally omitted. Proposed case numbering is not a registered reservation and requires final check before publication.
17. Verified References / পাঠ্যপুস্তক, গাইডলাইন ও DOI
- Harrison’s Principles of Internal Medicine. 22nd ed. McGraw Hill; 2025. Respiratory/allergic disease clinical chapters. Chapter/page not asserted without print edition access.
- Davidson’s Principles and Practice of Medicine. 25th ed. Elsevier; 2026. Respiratory disease / allergy content; exact page not verified.
- Dhingra PL, Dhingra S. Diseases of Ear, Nose and Throat & Head and Neck Surgery. Nasal obstruction/rhinitis and septal-deviation topic; consult available local edition. Exact edition/page not claimed.
- ARIA–EAACI 2024–2025 Guidelines: Intranasal treatments for allergic rhinitis. Allergy. DOI 10.1111/all.70131.
- Dykewicz MS, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020;146:721–767. DOI 10.1016/j.jaci.2020.07.007.
- Payne SC, et al. Clinical Practice Guideline: Adult Sinusitis Update. Otolaryngol Head Neck Surg. 2025. DOI 10.1002/ohn.1344.
- AAO-HNS 2025: Executive summary of adult sinusitis update. DOI 10.1002/ohn.1342.
- MedEx Bangladesh: primary drug monographs individually linked in Section 08. Brand identity, ingredient, listed price and pharmaceutical precautions crosschecked 03 Nov 2026; price/availability subject to change.
- Case numbers and department archive: LIPU MED medical archive and ENT department archive; checked 03 Nov 2026; not a guarantee of unpublished draft availability.
End of LIPU MED case review. Source: 1 prescription only; 0 laboratory reports; 0 additional clinical images. Publication status: draft, pending final case-number and prescription reconciliation.